Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roberto Miki is active.

Publication


Featured researches published by Roberto Miki.


JAMA | 2014

Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial

Alan W. Heldman; Darcy L. DiFede; Joel E. Fishman; Juan P. Zambrano; Barry Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R. Williams; Viky Y. Suncion; Ian McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard J. Willens; Robert C. Hendel; Raul Mitrani; Pradip M. Pattany; Gary S. Feigenbaum; Behzad Oskouei; John J. Byrnes; Maureen H. Lowery; Julio Sierra; Mariesty V. Pujol; Cindy Delgado; Phillip J. Gonzalez; Jose E Rodriguez; Luiza Bagno; Didier Rouy; Peter Altman

IMPORTANCE Whether culture-expanded mesenchymal stem cells or whole bone marrow mononuclear cells are safe and effective in chronic ischemic cardiomyopathy is controversial. OBJECTIVE To demonstrate the safety of transendocardial stem cell injection with autologous mesenchymal stem cells (MSCs) and bone marrow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy. DESIGN, SETTING, AND PATIENTS A phase 1 and 2 randomized, blinded, placebo-controlled study involving 65 patients with ischemic cardiomyopathy and left ventricular (LV) ejection fraction less than 50% (September 1, 2009-July 12, 2013). The study compared injection of MSCs (n=19) with placebo (n = 11) and BMCs (n = 19) with placebo (n = 10), with 1 year of follow-up. INTERVENTIONS Injections in 10 LV sites with an infusion catheter. MAIN OUTCOMES AND MEASURES Treatment-emergent 30-day serious adverse event rate defined as a composite of death, myocardial infarction, stroke, hospitalization for worsening heart failure, perforation, tamponade, or sustained ventricular arrhythmias. RESULTS No patient had a treatment-emergent serious adverse events at day 30. The 1-year incidence of serious adverse events was 31.6% (95% CI, 12.6% to 56.6%) for MSCs, 31.6% (95% CI, 12.6%-56.6%) for BMCs, and 38.1% (95% CI, 18.1%-61.6%) for placebo. Over 1 year, the Minnesota Living With Heart Failure score improved with MSCs (-6.3; 95% CI, -15.0 to 2.4; repeated measures of variance, P=.02) and with BMCs (-8.2; 95% CI, -17.4 to 0.97; P=.005) but not with placebo (0.4; 95% CI, -9.45 to 10.25; P=.38). The 6-minute walk distance increased with MSCs only (repeated measures model, P = .03). Infarct size as a percentage of LV mass was reduced by MSCs (-18.9%; 95% CI, -30.4 to -7.4; within-group, P = .004) but not by BMCs (-7.0%; 95% CI, -15.7% to 1.7%; within-group, P = .11) or placebo (-5.2%; 95% CI, -16.8% to 6.5%; within-group, P = .36). Regional myocardial function as peak Eulerian circumferential strain at the site of injection improved with MSCs (-4.9; 95% CI, -13.3 to 3.5; within-group repeated measures, P = .03) but not BMCs (-2.1; 95% CI, -5.5 to 1.3; P = .21) or placebo (-0.03; 95% CI, -1.9 to 1.9; P = .14). Left ventricular chamber volume and ejection fraction did not change. CONCLUSIONS AND RELEVANCE Transendocardial stem cell injection with MSCs or BMCs appeared to be safe for patients with chronic ischemic cardiomyopathy and LV dysfunction. Although the sample size and multiple comparisons preclude a definitive statement about safety and clinical effect, these results provide the basis for larger studies to provide definitive evidence about safety and to assess efficacy of this new therapeutic approach. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00768066.


Circulation Research | 2017

Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)

Victoria Florea; Angela C. Rieger; Darcy L. DiFede; Jill El-Khorazaty; Makoto Natsumeda; Monisha N. Banerjee; Bryon A. Tompkins; Aisha Khan; Ivonne Hernandez Schulman; Ana Marie Landin; Muzammil Mushtaq; Samuel Golpanian; Maureen H. Lowery; John J. Byrnes; Robert C. Hendel; Mauricio G. Cohen; Krystalenia Valasaki; Marietsy V. Pujol; Eduard Ghersin; Roberto Miki; Cindy Delgado; Fouad Abuzeid; Mayra Vidro-Casiano; Russell Saltzman; Daniel DaFonseca; Lina V. Caceres; Kevin Ramdas; Adam Mendizabal; Alan W. Heldman; Raul D. Mitrani

Rationale: Cell dose and concentration play crucial roles in phenotypic responses to cell-based therapy for heart failure. Objective: To compare the safety and efficacy of 2 doses of allogeneic bone marrow–derived human mesenchymal stem cells identically delivered in patients with ischemic cardiomyopathy. Methods and Results: Thirty patients with ischemic cardiomyopathy received in a blinded manner either 20 million (n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocardial injection (0.5 cc per injection × 10 injections per patient). Patients were followed for 12 months for safety and efficacy end points. There were no treatment-emergent serious adverse events at 30 days or treatment-related serious adverse events at 12 months. The Major Adverse Cardiac Event rate was 20.0% (95% confidence interval [CI], 6.9% to 50.0%) in 20 million and 13.3% (95% CI, 3.5% to 43.6%) in 100 million (P=0.58). Worsening heart failure rehospitalization was 20.0% (95% CI, 6.9% to 50.0%) in 20 million and 7.1% (95% CI, 1.0% to 40.9%) in 100 million (P=0.27). Whereas scar size reduced to a similar degree in both groups: 20 million by −6.4 g (interquartile range, −13.5 to −3.4 g; P=0.001) and 100 million by −6.1 g (interquartile range, −8.1 to −4.6 g; P=0.0002), the ejection fraction improved only with 100 million by 3.7 U (interquartile range, 1.1 to 6.1; P=0.04). New York Heart Association class improved at 12 months in 35.7% (95% CI, 12.7% to 64.9%) in 20 million and 42.9% (95% CI, 17.7% to 71.1%) in 100 million. Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20 million by 0.32 log pg/mL (95% CI, 0.02 to 0.62; P=0.039), but not in 100 million (−0.07 log pg/mL; 95% CI, −0.36 to 0.23; P=0.65; between group P=0.07). Conclusions: Although both cell doses reduced scar size, only the 100 million dose increased ejection fraction. This study highlights the crucial role of cell dose in the responses to cell therapy. Determining optimal dose and delivery is essential to advance the field, decipher mechanism(s) of action and enhance planning of pivotal Phase III trials. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02013674.


Journals of Gerontology Series A-biological Sciences and Medical Sciences | 2017

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Bryon A. Tompkins; Darcy L. DiFede; Aisha Khan; Ana Marie Landin; Ivonne Hernandez Schulman; Marietsy V. Pujol; Alan W. Heldman; Roberto Miki; Pascal J. Goldschmidt-Clermont; Bradley J. Goldstein; Muzammil Mushtaq; Silvina Levis-Dusseau; John J. Byrnes; Maureen H. Lowery; Makoto Natsumeda; Cindy Delgado; Russell Saltzman; Mayra Vidro-Casiano; Moisaniel Da Fonseca; Samuel Golpanian; Courtney Premer; Audrey Medina; Krystalenia Valasaki; Victoria Florea; Erica Anderson; Jill El-Khorazaty; Adam Mendizabal; Geoff Green; Anthony A. Oliva; Joshua M. Hare

Abstract Background Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair. Methods This is a randomized, double-blinded, dose-finding study of intravenous allo-hMSCs (100 or 200-million [M]) vs placebo delivered to patients (n = 30, mean age 75.5 ± 7.3) with frailty. The primary endpoint was incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion. Secondary endpoints included physical performance, patient-reported outcomes, and immune markers of frailty measured at 6 months postinfusion. Results No therapy-related TE-SAEs occurred at 1 month. Physical performance improved preferentially in the 100M-group; immunologic improvement occurred in both the 100M- and 200M-groups. The 6-minute walk test, short physical performance exam, and forced expiratory volume in 1 second improved in the 100M-group (p = .01), not in the 200M- or placebo groups. The female sexual quality of life questionnaire improved in the 100M-group (p = .03). Serum TNF-α levels decreased in the 100M-group (p = .03). B cell intracellular TNF-α improved in both the 100M- (p < .0001) and 200M-groups (p = .002) as well as between groups compared to placebo (p = .003 and p = .039, respectively). Early and late activated T-cells were also reduced by MSC therapy. Conclusion Intravenous allo-hMSCs were safe in individuals with aging frailty. Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome. Given the excellent safety and efficacy profiles demonstrated in this study, larger clinical trials are warranted to establish the efficacy of hMSCs in this multisystem disorder. Clinical Trial Registration www.clinicaltrials.gov: CRATUS (#NCT02065245).


Orthopedics | 2008

Anterior Tibial Artery and Deep Peroneal Nerve Entrapment in Spiral Distal Third Tibia Fracture

Roberto Miki; James P. Lawrence; Thomas J. Gillon; Brandon D. Lawrence; Richard A. Zell

The rate of injury to arterial structures following long bone injuries is low. The rate in tibial diaphyseal fractures is similarly low. This rate increases with open fractures, likely reflective of the higher energy nature of open fractures. The possibility of iatrogenic injury to neurovascular structures during fracture fixation is more concerning. Consequently, the clinician must be aware of the location of neurovascular structures and the possible distortion of the normal anatomy when treating fractures. The anterior tibial artery is in proximity to the distal tibia. Typically, the neurovascular bundle lies directly on the anterolateral tibia between the tibialis anterior and the extensor hallucis longus in the distal third of the tibia. After fracture, this normal relationship may be disrupted.


Hand | 2013

Hand fat grafting complicated by abscess: A case of a bilateral hand abscess from bilateral hand fat grafting

Alexander D. Vara; Roberto Miki; Daniel T. Alfonso; Roy Cardoso

Fat grafting has become popular in plastic surgery and dermatology where it is often used as physical filler, for scar prevention, or as a source of stem cells [7, 10]. Although complications are rare [1, 8], they have been reported in both settings. Complications of liposuction with autologous fat grafting include edema, fat necrosis, abdominal viscera perforation, hemorrhage, pulmonary embolism, hematoma, necrotizing fasciitis, abscess, and sepsis [3–6, 8, 9]. In this report, we present a case in which autologous fat grafting used as a cosmetic procedure resulted in bilateral hand abscesses.


Current Orthopaedic Practice | 2009

Evaluation of bone mineral density and metabolic abnormalities associated with low-energy hip fractures

Matthew E. Oetgen; Roberto Miki; L. Ryan Smart; Dieter M. Lindskog

Background Low-energy hip fractures are markers for osteoporosis. Despite a recent call for better evaluation of this issue, there is a lack of data regarding the metabolic abnormalities found in these patients and how it relates to their bone density. Additionally, no clear guidelines have been published for the evaluation of osteoporosis in these patients. We characterize the metabolic abnormalities seen in this patient population and suggest an effective screening protocol. Methods Thirty-one patients with low-energy hip fractures not receiving osteoporosis treatment were evaluated with bone density scans and a serum metabolic evaluation consisting of a 25-hydroxyvitamin D level, parathyroid hormone level, and calcium level. The relationship of metabolic abnormalities to bone density values was evaluated. Results Most of the patients presenting with low-energy hip fractures had metabolic abnormalities associated with low bone density. The femoral neck T-scores averaged −2.3. Fifty-three percent (16/30) of patients had low levels of vitamin D and 83% (25/30) of patients had evidence of secondary hyperparathyroidism (PTH >25 nleq/ml). We also found relatively poor correlations of bone density T-scores to parathyroid hormone and vitamin D levels (r=−0.38 and −0.05). Conclusion Most patients presenting with low energy hip fractures have severe metabolic abnormalities associated with low bone density. Due to the poor correlation between bone density T-scores and the serum levels of parathyroid hormone and vitamin D, appropriate osteoporosis evaluation of this patient population requires both bone density evaluation and serum metabolic evaluation of 25-hydroxyvitamin D, PTH, and calcium levels.


Hand | 2013

Erratum to: Carpal Coalition: A Review of Current Knowledge and Report of a Single Institution's Experience with Asymptomatic Intercarpal Fusion

Michael V. DeFazio; Benjamin J. Cousins; Roberto Miki; Roy Cardoso

The name of one of the authors, Roberto Augusto Miki Jr., was misspelled. We regret the error. The online version of the original article can be found at http://dx.doi.org/10.1007/s11552-013-9498-5.


Journal of the American College of Cardiology | 2017

Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial

Joshua M. Hare; Darcy L. DiFede; Angela C. Rieger; Victoria Florea; Ana Marie Landin; Jill El-Khorazaty; Aisha Khan; Muzammil Mushtaq; Maureen H. Lowery; John J. Byrnes; Robert C. Hendel; Mauricio G. Cohen; Carlos Alfonso; Krystalenia Valasaki; Marietsy V. Pujol; Samuel Golpanian; Eduard Ghersin; Joel E. Fishman; Pradip M. Pattany; Samirah A. Gomes; Cindy Delgado; Roberto Miki; Fouad Abuzeid; Mayra Vidro-Casiano; Courtney Premer; Audrey Medina; Valeria Porras; Konstantinos E. Hatzistergos; Erica Anderson; Adam Mendizabal


Journal of Bone and Joint Surgery, American Volume | 2008

Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial.

Roberto Miki; Matthew E. Oetgen; Jessica Kirk; Karl L. Insogna; Dieter M. Lindskog


The Iowa orthopaedic journal | 2009

Prevalence of methicillin resistant Staphylococcus aureus in upper extremity soft tissue infections at Jackson Memorial Hospital, Miami-Dade County, Florida.

Jodie A. Barkin; Roberto Miki; Zakariah Mahmood; David C. Landy; Patrick Owens

Collaboration


Dive into the Roberto Miki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge